Fibronectin and the critically ill patient: current status

Area of Science:

• Biochemistry
• Clinical Medicine
• Critical Care Medicine

Background:

• Plasma fibronectin deficiency is observed in diverse clinical settings.
• Persistently low fibronectin levels can serve as a prognostic indicator.
• Low fibronectin may suggest occult sepsis and impending organ failure.

Purpose of the Study:

• To summarize the clinical significance of plasma fibronectin deficiency.
• To highlight the potential prognostic value of fibronectin levels.
• To discuss the unresolved therapeutic role of fibronectin administration.

Main Methods:

• Review of clinical observations and literature regarding fibronectin deficiency.
• Analysis of the potential diagnostic and prognostic implications of low fibronectin.
• Evaluation of the current evidence for fibronectin-based therapies.

Main Results:

• Plasma fibronectin deficiency is associated with multiple clinical conditions.
• Sustained low fibronectin levels correlate with poor prognosis and risk of organ failure.
• The efficacy of fibronectin infusions remains unproven in rigorous clinical trials.

Conclusions:

• Plasma fibronectin deficiency is a recognized clinical finding with potential prognostic implications.
• Identifying low fibronectin may aid in diagnosing occult sepsis and predicting organ failure.
• Randomized controlled trials are essential to establish the therapeutic value of fibronectin infusions in critical care.